Evidence map›Paper›PMID 41669574›Full record

ArticleCureus2026

Valproic Acid and Famotidine Drug-Drug Interaction: Report of a Pediatric Case.

Mirei Kato, Lisa Mannina, Shelease O'Bryant, David Hart, Amber Mirajkar

Abstract readCase Reports
In one paragraph

Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Mirei KatoEmergency Medicine, Touro College of Osteopathic Medicine, Las Vegas, USA.
Lisa ManninaEmergency Medicine, Sunrise Health Graduate Medical Education (GME) Consortium, Hospital Corporation of America (HCA) Healthcare, Las Vegas, USA.
Shelease O'BryantPediatric Emergency Medicine, Sunrise Health Graduate Medical Education (GME) Consortium, Hospital Corporation of America (HCA) Healthcare, Las Vegas, USA.
David HartEmergency Medicine, Sunrise Health Graduate Medical Education (GME) Consortium, Hospital Corporation of America (HCA) Healthcare, Las Vegas, USA.
Amber MirajkarEmergency Medicine, Sunrise Health Graduate Medical Education (GME) Consortium, Hospital Corporation of America (HCA) Healthcare, Las Vegas, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Valproic acid is a broad-spectrum anticonvulsant medication that is used to treat multiple neurologic and psychiatric disorders such as epilepsy, bipolar disorder, schizophrenia, and migraine prophylaxis. Famotidine is an antacid used for various gastrointestinal conditions, including gastric and duodenal ulcers and gastroesophageal acid reflux disease (GERD). Acute ingestion of famotidine was found to inhibit anticonvulsant action and increase brain concentrations relative to free plasma levels in a mouse model. While they are not known to interact with one another, one of their proposed metabolisms is through the same CYP450 enzyme. However, a drug-drug interaction between valproic acid and famotidine, or this interaction causing toxicity in a child, is extremely rare. A 10-year-old male with a past medical history of bipolar disorder, posttraumatic stress disorder, and anxiety presented to a community emergency department (ED) with acute altered mental status and increasing somnolence. Routinely taking valproic acid, he had started prescription famotidine two days prior. In the ED, his valproic acid levels were six times the upper limit of normal with associated elevated creatinine and hypocalcemia. Later, hyperammonemia developed. He was ultimately treated with L-carnitine, lactulose, and meropenem as well as admitted to the pediatric intensive care unit (PICU) with normalization of lab values and complete resolution of his neurologic symptoms after 29 hours. This case describes an extremely rare drug-to-drug interaction of valproic acid and famotidine leading to acute altered mental status in a pediatric patient. While causality cannot be established from a single case, clinicians should consider this potential interaction when new medications are added to a stable valproic acid regimen, as these two medications are commonly prescribed in both adults and children.

Indexed as

cytochrome p450drug interactionemergency medicinefamotidinel-carnitinepediatric emergency medicinepharmacologytoxicologyvalproic acidvalproic acid toxicity

Identifiers

PMID41669574
PMCPMC12885040

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.